• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Madrigal Pharmaceuticals Inc.

    7/20/26 9:11:24 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MDGL alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001518611
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Madrigal Pharmaceuticals, Inc.
    SEC File Number
    Address of Issuer
    1001 Conshohocken State Road
    Suite 2-350
    West Conshohocken
    PENNSYLVANIA
    19428
    Phone
    267-824-2827
    Name of Person for Whose Account the Securities are To Be Sold
    William Sibold
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer and Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common Stock
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza, 8th Floor
    New York � NY � 10004
    250013837002305565907/20/2026
    Nasdaq Stock Market


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common Stock07/17/2026Performance Restricted Stock Unit GrantIssuerCheckbox not checked250007/17/2026Vesting of Performance Restricted Stock Units

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    The sale of shares of common stock reported on this Form 144 represents the sale of shares pursuant to a sell-to-cover transaction in order to satisfy certain tax withholding obligations in connection with the Reporting Owner earning Performance Restricted Stock Units previously granted to the Reporting Owner in September 2023.
    Date of Notice
    07/20/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ William Sibold

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $MDGL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDGL

    DatePrice TargetRatingAnalyst
    1/28/2026$964.00Overweight
    Barclays
    1/6/2026Outperform → Peer Perform
    Wolfe Research
    11/5/2025Neutral → Overweight
    Cantor Fitzgerald
    11/3/2025$445.00Underperform → Neutral
    BofA Securities
    10/15/2025$580.00Buy
    Truist
    9/4/2025$500.00Buy
    H.C. Wainwright
    2/28/2025$236.00 → $422.00Neutral → Buy
    B. Riley Securities
    2/27/2025$400.00 → $405.00Buy
    H.C. Wainwright
    More analyst ratings

    $MDGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Madrigal Pharmaceuticals with a new price target

    Barclays initiated coverage of Madrigal Pharmaceuticals with a rating of Overweight and set a new price target of $964.00

    1/28/26 7:18:07 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Madrigal Pharmaceuticals downgraded by Wolfe Research

    Wolfe Research downgraded Madrigal Pharmaceuticals from Outperform to Peer Perform

    1/6/26 8:41:07 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Madrigal Pharmaceuticals upgraded by Cantor Fitzgerald

    Cantor Fitzgerald upgraded Madrigal Pharmaceuticals from Neutral to Overweight

    11/5/25 7:24:00 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDGL
    SEC Filings

    View All

    SEC Form 144 filed by Madrigal Pharmaceuticals Inc.

    144 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

    7/20/26 9:11:24 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Madrigal Pharmaceuticals Inc.

    S-8 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)

    6/17/26 4:36:13 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Madrigal Pharmaceuticals Inc.

    8-K - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)

    6/17/26 4:06:04 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDGL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026

    CONSHOHOCKEN, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it will release its second-quarter 2026 financial results on Thursday, July 30, 2026, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results. The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. The webcast will be available approximately two ho

    7/16/26 8:00:00 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio

    Received two new U.S. Rezdiffra® (resmetirom) patents in F2/F3; both patents will be listed in the FDA’s Orange Book Received new U.S. resmetirom patent directed to a method of administering resmetirom to treat well-compensated cirrhosis (F4c) CONSHOHOCKEN, Pa., July 13, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that the United States Patent and Trademark Office (USPTO) issued three new resmetirom patents. Bill Sibold, Chief Executive Officer of Madrigal, stated: "Building a robust patent estate is a core pillar of

    7/13/26 8:00:00 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

    CONSHOHOCKEN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on July 1, 2026 to seven new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregat

    7/6/26 4:05:00 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baker Bros. Advisors Lp bought $36,941,197 worth of shares (97,065 units at $380.58) (SEC Form 4)

    4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

    8/20/25 6:12:22 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baker Bros. Advisors Lp bought $24,979,827 worth of shares (68,618 units at $364.04) (SEC Form 4)

    4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

    8/20/25 6:09:53 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Baker Bros. Advisors Lp bought $22,516,577 worth of shares (101,792 units at $221.20) (SEC Form 4)

    4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

    12/14/23 6:10:59 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Sibold William John converted options into 50,000 shares and sold $1,368,253 worth of shares (2,500 units at $547.30), increasing direct ownership by 29% to 209,329 units (SEC Form 4) to cover taxes

    4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

    7/20/26 9:16:52 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Taub Rebecca was granted 454 shares, increasing direct ownership by 0.10% to 452,667 units (SEC Form 4)

    4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

    6/18/26 4:23:26 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Levy Richard S was granted 454 shares, increasing direct ownership by 2% to 22,469 units (SEC Form 4)

    4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

    6/18/26 4:21:50 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDGL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for REZDIFFRA issued to MADRIGAL PHARMACEUTICALS INC

    Submission status for MADRIGAL PHARMACEUTICALS INC's drug REZDIFFRA (ORIG-1) with active ingredient RESMETIROM has changed to 'Approval' on 03/14/2024. Application Category: NDA, Application Number: 217785, Application Classification: Type 1 - New Molecular Entity

    3/14/24 3:35:50 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDGL
    Leadership Updates

    Live Leadership Updates

    View All

    Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH

    SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced that they have entered into an exclusive worldwide licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) ("Madrigal") for six pre-clinical small interfering RNA (siRNA) programs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The collaboration will utilize Ribo's validated liver targeting siRNA GalSTARTM platform to develop novel treatm

    2/11/26 6:25:00 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors

    Fred Craves, Ph.D. to retire from Madrigal's Board of Directors in July 2025 CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed Jacqualyn ("Jackie") Fouse, Ph.D. to its Board of Directors. Fred Craves, Ph.D. is retiring from the Board in July 2025. Julian Baker, Chairman of the Board of Directors, stated, "I am delighted to welcome Jackie Fouse to Madrigal. Jackie is an accomplished biotech executive who brings more than 30 years of healthcare industry and finance experience

    3/11/25 8:00:00 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development

    CONSHOHOCKEN, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), today announced the appointment of Michael R. Charlton, M.B.B.S., F.R.C.P., as Senior Vice President, Clinical Development, effective October 1, 2024. Becky Taub, M.D., Chief Medical Officer and President of Research & Development of Madrigal, stated, "I am thrilled to have Dr. Charlton joining the Madrigal team; his deep experience as a researcher and clinician treating patients with NASH will bring powerful new insights and ca

    10/1/24 8:00:00 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    $MDGL
    Financials

    Live finance-specific insights

    View All

    Amendment: SEC Form SC 13G/A filed by Madrigal Pharmaceuticals Inc.

    SC 13G/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

    11/14/24 5:18:50 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Madrigal Pharmaceuticals Inc.

    SC 13G - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

    11/14/24 6:30:21 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Madrigal Pharmaceuticals Inc. (Amendment)

    SC 13D/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

    3/25/24 4:28:21 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates

    First-quarter 2026 Rezdiffra® (resmetirom) net sales of $311.3 million, representing year-over-year growth of 127%As of March 31, 2026, more than 42,250 patients on Rezdiffra, up 2.5x from 1Q25, reflecting continued strong physician adoption and high patient demandAdvances pipeline with global licensing agreement for a clinical-stage siRNA asset targeting a mutation in the PNPLA3 gene, a genetically validated driver of MASHMGL-2086 (oral GLP-1) Phase 1 trial on track to initiate in 2Q26; ervogastat/resmetirom drug-drug interaction study on track to initiate in 4Q26 Reports cash, cash equivalents, restricted cash and marketable securities of $817.9 million as of March 31, 2026 Company to host

    5/6/26 7:00:00 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results

    Fourth-quarter and full-year 2025 Rezdiffra® (resmetirom) net sales of $321.1 million and $958.4 million, respectively As of year-end 2025, more than 36,250 patients on Rezdiffra Built industry-leading MASH pipeline with more than 10 programs at multiple stages of developmentReports cash, cash equivalents, restricted cash and marketable securities of $988.6 million as of Dec. 31, 2025Company to host conference call today, Feb. 19, 2026, at 8 a.m. EST CONSHOHOCKEN, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports

    2/19/26 7:00:00 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates

    Third-quarter 2025 Rezdiffra™ (resmetirom) net sales of $287.3 millionAs of September 30, 2025, more than 29,500 patients on Rezdiffra Closed global licensing agreement with CSPC Pharma to add oral GLP-1 to pipeline New Orange Book listed patent for Rezdiffra providing protection into 2045 Launched Rezdiffra in Germany following European Commission approval Reports cash, cash equivalents, restricted cash and marketable securities of $1.1 billion as of Sept. 30, 2025Company to host conference call today, Nov. 4, 2025, at 8 a.m. EST CONSHOHOCKEN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel thera

    11/4/25 7:00:00 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care